16
Dec
2021

Verge Genomics Gets $98M to Take ALS Drug to the Clinic

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

First, We Need to Generate the Right Data. Then AI Will Shine
Kyverna Gets $85M to Take CAR-T Cells for Autoimmunity To the Clinic
SQZ Shows Promise With HPV+ Cancer Vaccine in Early Solid Tumor Clinical Trial
Verge Genomics Strikes Deal with Lilly to Validate New Targets for ALS